CA2809779A1 - Fused triazoles for the treatment or prophylaxis of mild cognitive impairment - Google Patents

Fused triazoles for the treatment or prophylaxis of mild cognitive impairment Download PDF

Info

Publication number
CA2809779A1
CA2809779A1 CA2809779A CA2809779A CA2809779A1 CA 2809779 A1 CA2809779 A1 CA 2809779A1 CA 2809779 A CA2809779 A CA 2809779A CA 2809779 A CA2809779 A CA 2809779A CA 2809779 A1 CA2809779 A1 CA 2809779A1
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
group
salt
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2809779A
Other languages
English (en)
French (fr)
Inventor
Tatsuki Koike
Minoru Nakamura
Yoshihide Tomata
Takafumi Takai
Yasutaka Hoashi
Yuichi Kajita
Tetsuya Tsukamoto
Makoto Kamata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2809779(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA2809779A1 publication Critical patent/CA2809779A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2809779A 2010-09-02 2011-09-01 Fused triazoles for the treatment or prophylaxis of mild cognitive impairment Abandoned CA2809779A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2010-197064 2010-09-02
JP2010197064 2010-09-02
JP2011-143548 2011-06-28
JP2011143548 2011-06-28
PCT/JP2011/070419 WO2012029991A1 (en) 2010-09-02 2011-09-01 Fused triazoles for the treatment or prophylaxis of mild cognitive impairment

Publications (1)

Publication Number Publication Date
CA2809779A1 true CA2809779A1 (en) 2012-03-08

Family

ID=45094181

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2809779A Abandoned CA2809779A1 (en) 2010-09-02 2011-09-01 Fused triazoles for the treatment or prophylaxis of mild cognitive impairment

Country Status (22)

Country Link
US (3) US8822699B2 (cg-RX-API-DMAC7.html)
EP (1) EP2611805A1 (cg-RX-API-DMAC7.html)
JP (1) JP5871909B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130139895A (cg-RX-API-DMAC7.html)
CN (1) CN103249733A (cg-RX-API-DMAC7.html)
AR (1) AR082865A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011296887A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013004746A2 (cg-RX-API-DMAC7.html)
CA (1) CA2809779A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013000575A1 (cg-RX-API-DMAC7.html)
DO (1) DOP2013000051A (cg-RX-API-DMAC7.html)
EA (1) EA201390333A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012535A (cg-RX-API-DMAC7.html)
MA (1) MA34556B1 (cg-RX-API-DMAC7.html)
MX (1) MX2013002511A (cg-RX-API-DMAC7.html)
PE (1) PE20131305A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013500403A1 (cg-RX-API-DMAC7.html)
SG (1) SG187917A1 (cg-RX-API-DMAC7.html)
TW (1) TW201213327A (cg-RX-API-DMAC7.html)
UY (1) UY33586A (cg-RX-API-DMAC7.html)
WO (1) WO2012029991A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201301929B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482276A (zh) * 2009-07-13 2012-05-30 武田药品工业株式会社 杂环化合物及其用途
EA201390333A1 (ru) * 2010-09-02 2013-08-30 Такеда Фармасьютикал Компани Лимитед Конденсированные триазолы для лечения или профилактики умеренного когнитивного нарушения
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
RU2563254C2 (ru) * 2013-07-08 2015-09-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения производных 7-(гетеро)арил-4,5,6,7-тетрагидро[1,2,3]триазоло[1,5-a]пиридина
JP7000160B2 (ja) * 2015-05-12 2022-01-19 エフ エム シー コーポレーション 除草剤としてのアリール置換二環式化合物
US20210079182A1 (en) * 2019-09-12 2021-03-18 Dupont Electronics, Inc. Polyimide films and electronic devices
WO2023114456A1 (en) * 2021-12-17 2023-06-22 Athira Pharma, Inc. Uses of bicyclic compounds for the treatment of diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1261610A2 (en) 2000-02-17 2002-12-04 Bristol-Myers Squibb Pharma Company Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production
BRPI0410348A (pt) 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compostos e usos dos mesmos na modulação de amilóide-beta
US7402592B2 (en) * 2003-10-15 2008-07-22 Targacept, Inc. Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders
KR100966749B1 (ko) 2004-05-26 2010-06-30 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물
KR20070083781A (ko) 2004-10-26 2007-08-24 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물의 비정질체
US20090221611A1 (en) 2006-01-11 2009-09-03 Devita Robert J Fused Triazole Tachykinin Receptor Antagonists
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
HRP20120174T1 (hr) 2006-03-09 2012-03-31 Eisai R&D Management Co. Derivat policikličnog cinamida
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
WO2008077649A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infectons
TW200835502A (en) 2006-12-26 2008-09-01 Daiichi Sankyo Co Ltd Thiazepine derivatives
US8183276B2 (en) 2007-02-08 2012-05-22 Christian Fischer Therapeutic agents
CA2707712A1 (en) 2007-12-06 2009-06-11 Schering Corporation Gamma secretase modulators
TW201030002A (en) * 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2010197064A (ja) 2009-02-23 2010-09-09 Chugoku Electric Power Co Inc:The 直下位置測定装置
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012051806A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
RU2515976C2 (ru) * 2009-02-26 2014-05-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие конденсированные гетероциклические соединения и их применение в качестве ингибиторов продукции бета-амилоида
WO2011002067A1 (ja) 2009-07-02 2011-01-06 武田薬品工業株式会社 複素環化合物およびその用途
CN102482276A (zh) * 2009-07-13 2012-05-30 武田药品工业株式会社 杂环化合物及其用途
AP2011006034A0 (en) 2009-07-15 2011-12-31 Janssen Pharmaceuticals Inc Substituted triazole and imidazole derivatives as gamma secretase modulators.
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β-類澱粉生成之化合物
WO2011016559A1 (ja) 2009-08-07 2011-02-10 武田薬品工業株式会社 複素環化合物およびその用途
JP2011143548A (ja) 2010-01-12 2011-07-28 Panasonic Corp スクリーン印刷機及びスクリーン印刷方法
MX2012008260A (es) 2010-01-15 2012-08-17 Janssen Pharmaceuticals Inc Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa.
EA201390333A1 (ru) * 2010-09-02 2013-08-30 Такеда Фармасьютикал Компани Лимитед Конденсированные триазолы для лечения или профилактики умеренного когнитивного нарушения

Also Published As

Publication number Publication date
JP2013536798A (ja) 2013-09-26
WO2012029991A1 (en) 2012-03-08
JP5871909B2 (ja) 2016-03-01
ECSP13012535A (es) 2013-06-28
MA34556B1 (fr) 2013-09-02
PH12013500403A1 (en) 2013-03-25
ZA201301929B (en) 2013-11-27
DOP2013000051A (es) 2013-04-30
EP2611805A1 (en) 2013-07-10
TW201213327A (en) 2012-04-01
US20140350260A1 (en) 2014-11-27
SG187917A1 (en) 2013-04-30
PE20131305A1 (es) 2013-10-31
CN103249733A (zh) 2013-08-14
UY33586A (es) 2012-03-30
AR082865A1 (es) 2013-01-16
US8822699B2 (en) 2014-09-02
KR20130139895A (ko) 2013-12-23
EA201390333A1 (ru) 2013-08-30
AU2011296887A1 (en) 2013-04-11
US8901309B2 (en) 2014-12-02
US20130178497A1 (en) 2013-07-11
US20120059030A1 (en) 2012-03-08
MX2013002511A (es) 2013-07-29
CL2013000575A1 (es) 2013-08-23
BR112013004746A2 (pt) 2016-06-07

Similar Documents

Publication Publication Date Title
ES2716531T3 (es) Compuestos de 1-arilcarbonil-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas
AU2022334474A1 (en) Inhibitors of nlrp3
ES2695350T3 (es) Compuesto heterocíclico
US10017508B2 (en) Nitrogenated heterocyclic compound
US8822699B2 (en) Heterocyclic compound and use thereof
CA2767764A1 (en) Heterocyclic compound and use thereof
CN103402995A (zh) 新型吲哚、吲唑衍生物或其盐
CA3194376A1 (en) Hsd17b13 inhibitors and uses thereof
JP5888702B2 (ja) 抗癌活性化合物
WO2012008508A1 (ja) 複素環化合物
JP2012136500A (ja) 複素環化合物
WO2013005354A1 (ja) 複素環化合物
WO2013100018A1 (ja) 複素環化合物
HK1196368B (en) 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
HK1196368A (en) 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170901